查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1449602

全球诱导性多功能干细胞市场：按细胞来源、按应用、按最终用户、按地区

Global Induced Pluripotent Stem Cells Market, By Cell Source, By Application, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 164 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，诱导性多功能干细胞的全球市值为15.954亿美元，预计2024年至2031年复合年增长率为11.1%，到2031年达到37.07亿美元。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 15.954 亿美元
实际资料 2019-2023 预测期 2024-2031
预测期间 2023/2024 至 2030/2031 年复合年增长率： 11.10% 2030/2031 年预测值 37.07亿美元
图 1.诱导性多功能干细胞的全球市场占有率（%），按地区划分，2024 年
全球诱导性多能干细胞市场-IMG1

诱导性多功能干细胞（iPSC）是一种可以直接从成人细胞产生的多功能细胞。诱导性多功能干细胞的发现彻底改变了再生医学领域，因为它提供了伦理上优于胚胎干细胞的替代品。诱导性多功能干细胞(iPSC) 是一种经过基因重编程形成类似胚胎干细胞的多功能状态的成体细胞。 iPSC 用于再生医学研究，以研究疾病机制、药物发现和毒性筛检。 iPSC 的再生特性为开发以细胞为基础的治疗方法提供了机会。透过引入或过度表达关键转录因子，这些细胞将由多功能的成体细胞重新编程，使它们在分化潜力和多能性标记物的表达方面回归到与胚胎干细胞相似的状态。该技术对于开髮用于药物发现、毒性筛检和再生治疗的患者和疾病特异性干细胞模型具有广阔的前景。

市场动态：

全球诱导性多功能干细胞市场的推动因素包括慢性病的增加、器官移植的增加以及生物製药公司为开发利用干细胞的新型治疗方法而增加的研发投资。然而，iPS 细胞研究和临床应用的高成本以及细胞重编程和干细胞分化的技术挑战正在限制市场的成长。同时，干细胞技术不断进步，包括标准培养方法的开拓、无异源重编程方法的开发以及大规模干细胞生产的进步，预计将为市场参与者提供利润丰厚的成长机会。

本研究的主要特点

  • 本报告详细分析了全球诱导性多功能干细胞市场，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和复合年增长率。
  • 它还揭示了不同细分市场的潜在收益成长机会，并解释了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球诱导性多功能干细胞市场的主要企业进行了分析。
  • 本报告重点介绍了 Takara Bio、Thermo Fisher Scientific、 FUJIFILM Holdings Holdings、 Astellas Pharma、Fate Therapeutics、Ncardia、ViaCyte、Cellular Dynamics International、Lonza、Blueprint Medicines 和其他主要企业。
  • 该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球诱导性多功能干细胞市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。
  • 相关人员可以透过用于分析全球诱导性多功能干细胞市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 主要亮点
  • 监管场景
  • 最近的趋势
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 合併、收购和合作

第四章全球诱导性多功能干细胞市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球诱导性多功能干细胞市场（依细胞来源划分），2019-2031

  • 皮肤来源的 iPS 细胞
  • 血液来源的 iPS 细胞
  • 尿液来源的 iPSC
  • 肝细胞来源的 iPSC
  • 源自肺纤维母细胞的 iPSC
  • 其他（内皮细胞、神经胶质细胞、脂肪干细胞等）

第六章全球诱导性多功能干细胞市场（依应用），2019-2031

  • 文化/维护
  • 差异化
  • 基因操与工程
  • 表征和检验
  • 银行业务和存储
  • 其他（再程式化套件、分析软体等）

第 7 章 全球诱导性多功能干细胞市场，依最终用户划分，2019-2031 年

  • 医院
  • 诊断中心
  • 製药和生物技术公司
  • 受託研究机构
  • 其他（学术研究机构等）

第八章全球诱导性多功能干细胞市场（按地区），2019-2031

  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第9章 竞争格局

  • 公司简介
    • Takara Bio Inc.
    • Thermo Fisher Scientific
    • Fujifilm Holdings Corporation
    • Astellas Pharma
    • Fate Therapeutics
    • Ncardia
    • ViaCyte
    • Cellular Dynamics International
    • Lonza
    • Blueprint Medicines
    • Other Prominent Players

第10章

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6630

The global induced pluripotent stem cells market was valued at US$ 1,595.4 Mn in 2023 and is expected to reach US$ 3,707 Mn by 2031, growing at a compound annual growth rate (CAGR) of 11.1% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 1,595.4 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 11.10% 2030/2031 Value Projection: US$ 3,707 Mn
Figure 1. Global Induced Pluripotent Stem Cells Market Share (%), By Region, 2024
Global Induced Pluripotent Stem Cells Market - IMG1

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The discovery of induced pluripotent stem cells revolutionized the field of regenerative medicine as it provided an ethically superior alternative to embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like pluripotent state. iPSCs are used in regenerative medicine research to study mechanisms of disease and for drug discovery and toxicity screening. Regenerative properties of iPSCs provide opportunities for developing cell-based therapies. These cells are reprogrammed from their original differentiated adult cells through the introduction or overexpression of key transcription factors that enable them to regress to a state that resembles embryonic stem cells in terms of differentiation potential and expression of pluripotency markers. This technology holds tremendous promise for developing patient and disease specific stem cell models for drug discovery, toxicity screening, and regenerative therapies.

Market Dynamics:

Global induced pluripotent stem cells market is driven by rising prevalence of chronic diseases, increasing adoption of organ transplantation and growing research and development (R&D) investments by biopharmaceutical companies for developing novel stem cell-based therapies. However, high costs that are associated with iPSC research and clinical applications, technical challenges in cell reprogramming and stem cell differentiation are restraining wider market growth. Meanwhile, ongoing advancements in stem cell technologies including establishment of standard culture practices, development of xeno-free reprogramming methods and progress in large-scale stem cell production are expected to offer lucrative growth opportunities for market players.

Key features of the study:

  • This report provides an in-depth analysis of the global induced pluripotent stem cells market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global induced pluripotent stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • The key companies covered as a part of this study include Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines, and Other Prominent Players.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global induced pluripotent stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global induced pluripotent stem cells market.

Detailed Segmentation:

  • By Cell Source:
    • Skin derived iPSCs
    • Blood derived iPSCs
    • Urine Derived iPSCs
    • Hepatocytes derived iPSCs
    • Lung fibroblast derived iPSCs
    • Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
  • By Application:
    • Culture & Maintenance
    • Differentiation
    • Genetic Manipulation & Engineering
    • Characterization & Validation
    • Banking & Storage
    • Others (Reprogramming kits, Analysis software etc.)
  • By End User:
    • Hospitals
    • Diagnostics Centers
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations
    • Others (Academic & Research Institutes etc.)
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Top Companies in the Global Induced Pluripotent Stem Cells Market
    • Takara Bio Inc.
    • Thermo Fisher Scientific
    • Fujifilm Holdings Corporation
    • Astellas Pharma
    • Fate Therapeutics
    • Ncardia
    • ViaCyte
    • Cellular Dynamics International
    • Lonza
    • Blueprint Medicines
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Induced Pluripotent Stem Cells Market Snippet, By Cell Source
    • Global Induced Pluripotent Stem Cells Market Snippet, By Application
    • Global Induced Pluripotent Stem Cells Market Snippet, By End User
    • Global Induced Pluripotent Stem Cells Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Induced Pluripotent Stem Cells Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Induced Pluripotent Stem Cells Market, By Cell Source, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Skin derived iPSCs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Blood derived iPSCs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Urine Derived iPSCs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Hepatocytes derived iPSCs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Lung fibroblast derived iPSCs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Induced Pluripotent Stem Cells Market, By Application, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Culture & Maintenance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Differentiation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Genetic Manipulation & Engineering
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Characterization & Validation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Banking & Storage
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others (Reprogramming kits, Analysis software etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Induced Pluripotent Stem Cells Market, By End User, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Diagnostics Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Pharmaceutical & Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Contract Research Organizations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others (Academic & Research Institutes etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Induced Pluripotent Stem Cells Market, By Region, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 - 2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
  • South Africa
  • North Africa
  • Central Africa

9. Competitive Landscape

  • Company Profile
    • Takara Bio Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Fujifilm Holdings Corporation
    • Astellas Pharma
    • Fate Therapeutics
    • Ncardia
    • ViaCyte
    • Cellular Dynamics International
    • Lonza
    • Blueprint Medicines
    • Other Prominent Players
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us